- Biogen counts on drugs from Apellis deal to patch Leqembi's slow salesIt’s no secret that sales of Leqembi have been disappointing. First approved in 2023, the Alzheimer’s drug from Eisai and Biogen launched shortly after Chris Viehbacher took the reins as Biogen C…Endpoints · 1d ago↗ source
- What’s behind the proposed pullback on remote patient monitoringCompanies that help doctors keep tabs on their patients at home are freaking out after Medicare's proposal last week to gut remote patient monitoring, or RPM. The plan is a total about-face from…Endpoints · 1d ago↗ source
- Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansionPlus, news about Lonza, Bachem and Samsung Biologics. 🤝 Repligen to acquire BioLife Solutions: Repligen will pay around $1.5 billion for cell processing service supplier BioLife, 36% of which w…